BACKGROUND: Tranexamic acid (TXA) has been shown to reduce blood loss in surgical
patients and the risk of death in patients with traumatic bleeding, with no apparent increase …

Objective The antifibrinolytic agent tranexamic acid (TXA) has demonstrated clinical benefit
in trauma patients with severe bleeding, but its effectiveness in patients with traumatic brain …

Background Traumatic brain injury (TBI) is commonly accompanied by intracranial bleeding
which can worsen after hospital admission. Tranexamic acid (TXA) has been shown to …

Background: Worldwide, traumatic brain injury (TBI) kills or hospitalises over 10 million
people each year. Early intracranial bleeding is common after TBI, increasing the risk of …

Background Women are less likely than men to receive some emergency treatments. This
study examines whether the effect of tranexamic acid (TXA) on mortality in trauma patients …

Tranexamic acid (TXA) reduces blood loss by inhibiting the enzymatic breakdown of fibrin. It
is often used in surgery to decrease bleeding and the need for blood transfusion. In 2011 …

Objective To assess the effect of tranexamic acid (which reduces bleeding in surgical
patients and reduces mortality due to bleeding in trauma patients) on intracranial …

BACKGROUND Tranexamic acid safely reduces mortality in traumatic extracranial bleeding.
Intracranial bleeding is common after traumatic brain injury and can cause brain herniation …

Background Tranexamic acid reduces surgical bleeding and decreases mortality in patients
with traumatic extracranial bleeding. Intracranial bleeding is common after traumatic brain …

Objective To describe the use of tranexamic acid (TXA) in trauma care in England and
Wales since the Clinical Randomization of an Antifibrinolytic in Significant Hemorrhage …